Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2002 | 2 |
2005 | 1 |
2008 | 1 |
2009 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
Mol Cancer Ther. 2002 Aug;1(10):841-9.
Mol Cancer Ther. 2002.
PMID: 12492117
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.
Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F.
Pavlick AC, et al.
Cancer Chemother Pharmacol. 2009 Sep;64(4):803-10. doi: 10.1007/s00280-009-0931-y. Epub 2009 Feb 17.
Cancer Chemother Pharmacol. 2009.
PMID: 19221754
Free PMC article.
Clinical Trial.
Item in Clipboard
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.
Hamilton AL, et al.
J Clin Oncol. 2005 Sep 1;23(25):6107-16. doi: 10.1200/JCO.2005.01.136.
J Clin Oncol. 2005.
PMID: 16135477
Clinical Trial.
Item in Clipboard
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.
Muggia FM, Liebes L, Hazarika M, Wadler S, Hamilton A, Hornreich G, Sorich J, Chiang C, Newman E, Potmesil M, Hochster H.
Muggia FM, et al.
Anticancer Drugs. 2002 Sep;13(8):819-25. doi: 10.1097/00001813-200209000-00006.
Anticancer Drugs. 2002.
PMID: 12394266
Clinical Trial.
Item in Clipboard
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP; National Cancer Institute Organ Dysfunction Working Group.
Ramanathan RK, et al.
J Clin Oncol. 2008 Feb 1;26(4):563-9. doi: 10.1200/JCO.2007.11.0304.
J Clin Oncol. 2008.
PMID: 18235115
Clinical Trial.
Item in Clipboard
Cite
Cite